FDA Grants Ceragenix's Request for Cerashield(TM) to be Reviewed as a Device (Business Wire via Yahoo! Finance)
DENVER----June 14, 2006--Ceragenix Pharmaceuticals, Inc. today announced that the FDA's Office of Combination Products in response to the Company's formal request has determined that Cerashield's primary mode of action is that of a device and it has been assigned to the FDA's Center for Devices and Radiologic Health for lead review.

Baxter gets tentative OKs for generic Zofran (India Daily)
Baxter International Inc. late Thursday said it has received tentative approvals from the Food and Drug Administration for a generic version of GlaxoSmithKline Plc's Zofran, used to prevent nausea and vomiting.

Baxter Receives Tentative FDA Approvals For Ondansetron Injection In Vials And Premix Containers (PR Newswire via Yahoo! Finance)
Baxter Healthcare Corporation today announced that it has received tentative approvals from the U.S. Food and Drug Administration for Ondansetron Injection USP, including the first tentative approval for a premix version of GlaxoSmithKline's Zofran , which is used for the prevention of nausea and vomiting.